Aurobindo Pharma Ltd. announced its quarterly results on August 12, 2020. Consolidated net revenue in Q1FY21 stood at Rs5,924.78cr, which increased by 8.82% yoy from Rs5,444.6cr in Q1FY20.
EBITDA stood at Rs1,257.35cr in Q1FY21 that increased by 9.68% yoy. For Q1FY20, it posted EBITDA of Rs1,146.4cr. EBITDA margin as of Q1FY21 was at 21.22% that increased by 16bps yoy against the same quarter, the previous year.
The consolidated net profit in Q1FY21 came in at Rs780.68cr that increased by 22.81% yoy, as compared to Q1FY20, when it reported Rs635.68cr. The net profit margin in Q1FY21 came in at 13.18% that increased by 1.5% yoy. The net profit margin for Q1FY20 was at 11.68%.
The share price of company closed at Rs934 with decline of 1.14% in today’s session on BSE.
|
Particulars |
Q1FY21 (Rs in cr) |
Q1FY20 (Rs in cr) |
% VAR |
|
Net Revenue |
5,924.78 |
5,444.60 |
8.82 |
|
Operating Profit |
1,257.35 |
1,146.40 |
9.68 |
|
Net Profit |
780.68 |
635.68 |
22.81 |
|
EBITDAM% |
21.22 |
21.06 |
16bps |
|
PATM% |
13.18 |
11.68 |
1.50 |
Related Tags:
